Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from PainChek Ltd ( (AU:PCK) ).
PainChek Ltd reported progress in its quarterly update, highlighting the submission of a De Novo regulatory request to the US FDA, which is expected to expand its business into the US market. The company has achieved significant growth in user implementation with 100,000 contracted licenses globally, reflecting a 22% increase from the previous year. Moreover, the Infant App launched positively in the market, with plans to expand into the direct-to-consumer sector by mid-2025. PainChek has also maintained high customer retention rates and secured a significant increase in revenue, positioning itself strongly in its industry and enhancing shareholder value.
More about PainChek Ltd
PainChek Ltd is a company that develops smart device-based pain assessment and monitoring applications. The company focuses on providing pain assessment solutions for both adults and infants, with significant market penetration in aged care facilities and a growing presence in home care and hospital markets.
YTD Price Performance: -10.0%
Average Trading Volume: 781,208
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$48.81M
See more insights into PCK stock on TipRanks’ Stock Analysis page.
